Overview

• Healthcare technology firm's Q3 revenue grew 8.7%, beating analyst expectations

• Adjusted EPS for Q3 beat analyst expectations

• Cardiac Ablation Solutions revenue increased 80%, driven by pulsed field ablation portfolio

Outlook

• Medtronic reiterates FY26 organic revenue growth of approximately 5.5%

• Medtronic expects FY26 non-GAAP EPS of $5.62 to $5.66

• Company anticipates $185 mln tariff impact on FY26 results

Result Drivers

• CARDIAC ABLATION GROWTH - Revenue from Cardiac Ablation Solutions rose 80%, driven by the pulsed field ablation portfolio

• DIABETES SEGMENT - Diabetes revenue increased 8.3%, led by double-digit growth in international markets

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Medtronic PLC is $112.17, about 12.7% above its February 13 closing price of $99.49

• The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nCNWpfV2ta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)